公开(公告)号：US20240067714A1

公开(公告)日：2024-02-29

申请号：US18025792

申请日：2021-09-13

Applicant: LIMMATECH BIOLOGICS AG

Inventor： Manuela MALLY ,  Amirreza FARIDMOAYER ,  Rainer FOLLADOR ,  Jonathan Albert BACK

IPC: C07K16/24

CPC classification number: C07K16/241 ,  A61K2039/545 ,  C07K2317/14 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/94

Abstract: The present disclosure provides monoclonal antibodies (e.g., anti-TNFα antibodies) having Fab sialylation, and, in some aspects, Fab sialylation in combination with an afucosylated Fc. Such antibodies having improved immunogenicity profiles and related advantages. Such glycan modifications will improve current treatments and allow a better quality of life for patients. Accordingly, such monoclonal antibodies are useful for treating and preventing various diseases.

公开(公告)号：US11912761B2

公开(公告)日：2024-02-27

申请号：US17150689

申请日：2021-01-15

Applicant: Agency for Science, Technology and Research

Inventor： Cheng-I Wang ,  Angeline Goh ,  Siok Ping Yeo ,  Alessandra Rosa Mortellaro ,  Subhra Kumar Biswas ,  Florent Ginhoux ,  Pingyu Zhong

IPC: A61K39/395 ,  C07K16/24 ,  A61K39/00

CPC classification number: C07K16/245 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2317/10 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention is directed to antigen binding proteins and in particular to IL-1β antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production.

公开(公告)号：US11905318B2

公开(公告)日：2024-02-20

申请号：US17011059

申请日：2020-09-03

Applicant: The University of British Columbia

Inventor： Neil R. Cashman ,  Steven S. Plotkin

IPC: C07K7/00 ,  C07K14/00 ,  A61K38/00 ,  A61K38/08 ,  A61K38/10 ,  A61K38/12 ,  A61K38/17 ,  C07K14/47 ,  C07K16/18 ,  C07K5/103 ,  C07K5/117 ,  A61K47/64 ,  C07K7/06 ,  C12N5/10 ,  C07K7/64 ,  A61P25/28 ,  A61K39/00 ,  A61K39/39 ,  A61K51/10 ,  G01N33/68 ,  A61K49/18 ,  A61K39/395 ,  A61K38/07 ,  A61K47/68 ,  A61K45/00 ,  A61K51/08 ,  A61K47/69 ,  A61K38/05 ,  A61K45/06 ,  C07K7/08 ,  C07K16/00 ,  C07K14/435 ,  G01N33/50 ,  A61L27/22 ,  A61L27/34 ,  A61L31/10 ,  A61L31/16 ,  A61L29/08 ,  A61L29/16

CPC classification number: C07K14/4711 ,  A61K38/1716 ,  A61K39/0007 ,  A61K39/39 ,  A61K47/643 ,  A61K47/646 ,  A61K51/1018 ,  A61P25/28 ,  C07K5/101 ,  C07K5/1024 ,  C07K7/06 ,  C07K7/64 ,  C07K16/18 ,  C12N5/10 ,  G01N33/6896 ,  A61K38/00 ,  A61K38/05 ,  A61K38/07 ,  A61K38/08 ,  A61K38/12 ,  A61K39/00 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/39533 ,  A61K45/05 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6921 ,  A61K49/1818 ,  A61K49/1866 ,  A61K51/088 ,  A61K51/10 ,  A61K2039/505 ,  A61K2039/55505 ,  A61K2039/6081 ,  A61K2300/00 ,  A61L27/227 ,  A61L27/34 ,  A61L29/085 ,  A61L29/16 ,  A61L31/10 ,  A61L31/16 ,  C07K7/08 ,  C07K14/435 ,  C07K16/00 ,  C07K2317/20 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/624 ,  C07K2317/626 ,  C07K2317/70 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00 ,  G01N33/5058 ,  G01N2333/4709 ,  G01N2800/28 ,  G01N2800/2821 ,  G01N2800/387

Abstract: The disclosure pertains to conformational epitopes in A-beta, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.

公开(公告)号：US11904053B2

公开(公告)日：2024-02-20

申请号：US17081821

申请日：2020-10-27

Applicant: MedImmune Limited

Inventor： Catherine Eugenie Chaillan Huntington ,  Susan Hoe ,  Prakash Manikwar ,  Roland Wilhelm Kolbeck ,  Emma Suzanne Cohen ,  David Lechuga-Ballesteros ,  Kellisa Beth Hansen ,  Dexter Joseph D'Sa ,  Saba Ghazvini

IPC: A61K9/16 ,  A61K39/00 ,  A61K47/26 ,  A61K9/00 ,  C07K16/24 ,  C07K14/54

CPC classification number: A61K9/1623 ,  A61K9/0075 ,  A61K9/1652 ,  C07K16/244 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/565

Abstract: The present technology relates generally to dry powder formulations of antibodies specific for thymic stromal lymphopoietin (TSLP), as well as methods of treating asthma, using the dry powder formulations, suitably via pulmonary delivery.

公开(公告)号：US20240052023A1

公开(公告)日：2024-02-15

申请号：US18449190

申请日：2023-08-14

Applicant: Agency for Science, Technology and Research

Inventor： Frederic Bard ,  Anh Tuan Nguyen ,  Ros Manon

IPC: C07K16/18

CPC classification number: C07K16/18 ,  C07K2317/622 ,  C07K2317/54 ,  C07K2317/24 ,  C07K2317/55

Abstract: We describe a Cnx/ERp57 inhibitor for use in the treatment or prevention of cancer.

公开(公告)号：US20240034814A1

公开(公告)日：2024-02-01

申请号：US18256276

申请日：2021-12-07

Applicant: Janux Therapeutics, Inc.

Inventor： David CAMPBELL ,  Thomas R. DIRAIMONDO ,  Ramesh BHATT

IPC: C07K16/46

CPC classification number: C07K16/468 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2317/55 ,  C07K2317/31

Abstract: Disclosed herein are polypeptides and polypeptides complexes comprising a half-life extending antibody or antibody fragment. In some embodiments, the half-life extending antibody or antibody fragment is a single domain antibody.

公开(公告)号：US11884737B2

公开(公告)日：2024-01-30

申请号：US17361393

申请日：2021-06-29

Applicant: UCB BIOPHARMA SRL ,  BIOGEN MA INC.

Inventor： Ruth Oliver ,  Miren Zamacona

IPC: C07K16/02 ,  A61K39/395 ,  A61P37/06 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2875 ,  A61K39/395 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/35 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to a method of treating an autoimmune or inflammatory disease or a neurodegenerative disease with an antibody to CD154.

公开(公告)号：US20240026031A1

公开(公告)日：2024-01-25

申请号：US17773283

申请日：2020-10-30

Applicant: The Regents of the University of California

Inventor： James A. WELLS ,  Adam D. COTTON ,  Duy NGUYEN ,  Katarina PANCE

IPC: C07K16/40 ,  C07K16/28 ,  A61K47/68

CPC classification number: C07K16/40 ,  C07K16/2827 ,  A61K47/6879 ,  A61K47/6803 ,  C07K2317/55 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2317/92

Abstract: The present disclosure relates to, among other things, methods for degrading targeted surface proteins using the ubiquitin pathway by using a bispecific binding agent or an immunoconjugate that binds the targeted surface protein and a membrane-associated ubiquitin E3 ligase. The present disclosure also relates to methods for degrading targeted surface proteins using the ubiquitin pathway using an engineered transmembrane protein that binds the targeted surface protein and exhibits ubiquitin E3 ligase activity. The disclosure also provides compositions and methods useful for producing such bispecific binding agents and engineered transmembrane proteins, immunoconjugates, nucleic acids encoding same, host cells genetically modified with the nucleic acids, as well as methods for modulating an activity of a cell and/or for the treatment of various diseases such as cancers.

公开(公告)号：US20240026002A1

公开(公告)日：2024-01-25

申请号：US18452395

申请日：2023-08-18

Applicant: Xencor, Inc.

Inventor： Matthew J. Bernett ,  Gregory Moore ,  John Desjarlais ,  Michael Hedvat ,  Christine Bonzon

IPC: C07K16/28 ,  A61P35/00 ,  A61P37/06

CPC classification number: C07K16/2818 ,  A61P35/00 ,  A61P37/06 ,  C07K16/2803 ,  C07K16/2827 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/52 ,  C07K2317/33 ,  C07K2317/31 ,  A61K2039/507

Abstract: The present invention is directed to bispecific, heterodimeric immunomodulatory antibodies.

公开(公告)号：US11878058B2

公开(公告)日：2024-01-23

申请号：US17306395

申请日：2021-05-03

Applicant: Sorrento Therapeutics, Inc.

Inventor： Heyue Zhou ,  Randy Gastwirt ,  Barbara A. Swanson ,  John Dixon Gray ,  Gunnar F. Kaufmann

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61K39/00

CPC classification number: A61K39/39541 ,  A61P35/00 ,  C07K16/28 ,  C07K16/2818 ,  C07K16/2827 ,  A61K2039/505 ,  A61K2121/00 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-L1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-L1, PD-L1-binding fragments and derivatives of such antibodies, and PD-L1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-L1 related disorders or conditions, including various inflammatory disorders and various cancers.